Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 1.00 |
| ▸ | DRD3 | P35462 | 15/20 | 1.00 |
| ▸ | DRD4 | P21917 | 5/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | DRD5 | P21918 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193607 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4HTR2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL5366724 | 0.89 | DRD2 (0.81) | DRD2DRD3DRD4HTR2ASLC6A2 | |
| SCHEMBL1193610 | 0.89 | DRD2 (0.81) | DRD2DRD3DRD4HTR2ASLC6A2 | |
| SCHEMBL9565812 | 0.88 | DRD2 (0.79) | DRD2DRD3 | |
| SCHEMBL14494921 | 0.87 | DRD2 (0.77) | DRD2DRD3DRD4HTR2ADRD5 | |
| SCHEMBL14494936 | 0.85 | DRD2 (0.74) | DRD2DRD3DRD4HTR2ADRD5 | |
| SCHEMBL11745974 | 0.84 | DRD2 (0.73) | DRD2DRD3HTR2ASLC6A4 | |
| SCHEMBL2782258 | 0.84 | DRD2 (1.00) | DRD2DRD3DRD4HTR2ADRD5 | |
| SCHEMBL1896873 | 0.84 | DRD2 (0.72) | DRD2DRD3DRD4HTR2ADRD5 | |
| SCHEMBL14494878 | 0.83 | DRD2 (0.76) | DRD2DRD3DRD4HTR2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220060-B1 | TETRAHYDROBENZOTHIAZOLE DERIVATIVES | MOTAC NEUROSCIENCE LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-8389555-B2 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110046153-A1 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2220060-A1 | MEDICAMENTS | Motac Neuroscience Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056805-A1 | MEDICAMENTS | MOTAC NEUROSCIENCE LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| EP-0094159-B1 | DIHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-03-14 | — | — | EP | disclosed |
| US-4892875-A | HYPOTENSIVE, RENAL VASODILATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-01-09 | — | — | US | disclosed |
| EP-0094159-A1 | Dihydropyridine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | DRD2 2/4885DRD3 3/4885DRD4 4/4885 |
| US-20110046153-A1 | Medicaments | MTNR1A, SIGMAR1, OPRK1 | DRD2 16/4885DRD3 41/4885DRD4 40/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | DRD2 2/4885DRD3 3/4885DRD4 4/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | DRD2 2/4885DRD3 3/4885DRD4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.